Evidence map›Paper›PMID 33376575›Full record

ArticleThe World Allergy Organization journal2021

First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients.

Karl-Christian Bergmann, Linda Krause, Julia Hiller, Sylvia Becker, Sebastian Kugler, Martin Tapparo, Oliver Pfaar, Torsten Zuberbier, Matthias F Kramer, Sonja Guethoff and 1 more

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Karl-Christian BergmannDepartment for Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Berlin, Germany.
Linda KrauseInstitute of Medical Biometry and Epidemiology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
Julia HillerBencard Allergie GmbH, Munich, Germany.
Sylvia BeckerECARF - European Centre for Allergy Research Foundation, Berlin, Germany.
Sebastian KuglerECARF - European Centre for Allergy Research Foundation, Berlin, Germany.
Martin TapparoBencard Allergie GmbH, Munich, Germany.
Oliver PfaarDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Torsten ZuberbierDepartment for Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Berlin, Germany.
Matthias F KramerBencard Allergie GmbH, Munich, Germany.
Sonja GuethoffBencard Allergie GmbH, Munich, Germany.
Anke GraesselBencard Allergie GmbH, Munich, Germany.
Allergy Therapeutics (United Kingdom) · GBCharité - Universitätsmedizin Berlin · DEPhilipps University of Marburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllergic rhinitis/rhinoconjunctivitis is the most common immune disease worldwide, but still largely underestimated, underdiagnosed, and undertreated. Dysbiosis and reduced microbial diversity is linked to the development of allergies, and the immunomodulatory effects of pro- and prebiotics might be used to counteract microbiome dysbiosis in allergy. Adequate symbiotic (multi-strain pro-, plus prebiotic) supplementation can be suggested as a complementary approach in the management of allergic rhinitis.

objectiveThe effects of the daily intake of a symbiotic food supplement (combination of

methodsEligible patients were exposed to birch pollen (8000 pollen/m³ for 120 min) at the GA

results27 patients (mean age 45 years, 15% male) completed the study. Both co-primary endpoints showed significant improvement after intake of the symbiotic. Median TNSS and TSS were decreased 50% and 80% at 120 min (adjusted p-value = 0.025 and p < 0.01 respectively).All four symptom scores and the personal well-being, improved to a clinically relevant extent over time, visible by a weaker increase in symptoms during 120 min of the final birch pollen exposure. No relevant differences were observed for PNIF, PEF, and spirometry. There were no airway obstructions or lung restrictions before and after both exposures. Late phase reactions after exposure were reduced after V3, documenting a better birch pollen tolerability of the patients. The safety and tolerability profile of the symbiotic food supplement was excellent, no adverse events (AEs) were observed.

conclusionsThis first evaluation of a symbiotic food supplement in an AEC in rhinoconjunctivitis patients with or without asthma induced by birch pollen revealed a significant beneficial effect, harnessing significant improvements of symptoms and well-being while maintaining an excellent safety and tolerability profile.

Indexed as

Allergen exposure chamber (AEC)Birch pollen allergyFood supplementPeak expiratory flow (PEFBackspace)Peak nasal inspiratory flow (PNIF)ProbioticSymbioticTotal symptom score (TSS)

Identifiers

PMID33376575
PMCPMC7753943
OpenAlexW3115003457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.